This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Robinson, M. K. Articles by Adams, G. P. PubMed PubMed Citation Articles by Robinson, M. K. Articles by Adams, G. P.

Effective Treatment of Established Human Breast Tumor Xenografts in Immunodeficient Mice with a Single Dose of the -Emitting Radioisotope Astatine-211 Conjugated to Anti-HER2/neu Diabodies

Authors' Affiliations: ¹ Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; ² National Cancer Institute, NIH, Bethesda, Maryland; and ³ Department of Anesthesiology and Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, California

Requests for reprints: Gregory P. Adams, Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. Phone: 215-728-3890; Fax: 215-728-2741; E-mail: gp_adams{at}fccc.edu.

Purpose: Successful radioimmunotherapy strategies depend on selecting radioisotopes with physical properties complementary to the biological properties of the targeting vehicle. Small, engineered antitumor antibody fragments are capable of rapid, highly specific tumor targeting in immunodeficient mouse models. We hypothesized that the C6.5 diabody, a noncovalent anti-HER2 single-chain Fv dimer, would be an ideal radioisotope carrier for the radioimmunotherapy of established tumors using the short-lived -emitting radioisotope ²¹¹At.

Experimental Design: Immunodeficient nude mice bearing established HER2/neu–positive MDA-MB-361/DYT2 tumors treated with N-succinimidyl N-(4-[²¹¹At]astatophenethyl)succinamate (²¹¹At-SAPS)-C6.5 diabody. Additional cohorts of mice were treated with ²¹¹At-SAPS T84.66 diabody targeting the carcinoembryonic antigen or ²¹¹At-SAPS on a diabody specific for the Müllerian inhibiting substance type II receptor, which is minimally expressed on this tumor cell line.

Results: A single i.v. injection of ²¹¹At-SAPS C6.5 diabody led to a 30-day delay in tumor growth when a 20 µCi dose was administered and a 57-day delay in tumor growth (60% tumor-free after 1 year) when a 45 µCi dose was used. Treatment of mice bearing the same tumors with ²¹¹At-SAPS T84.66 diabody at the same doses led to a delay in tumor growth, but no complete responses, likely due to substantially lower expression of this antigen on the MDA-MB-361/DYT2 tumors. In contrast, a dose of 20 µCi of ²¹¹At-SAPS on the anti–Müllerian-inhibiting substance type II receptor diabody did not affect tumor growth rate, demonstrating specificity of the therapeutic effect.

Conclusions: These findings indicate that diabody molecules can be effective agents for targeted radioimmunotherapy of solid tumors using powerful, short-lived -emitting radioisotopes.